81 results about "Diabetic complication" patented technology

The invention relates to lauroyl cilostazol as well as a preparation method and application thereof. Wherein the lauroyl cilostazol is sterile, and preferably, the lauroyl cilostazol is a crystal. The invention further provides application of the lauroyl cilostazol in preparing medicines for treating cerebral infarction, cerebrovascular diseases, atherosclerosis, diabetic complications, peripheral vascular diseases, Reynolds diseases, intermittent claudication, ischemic heart diseases and acute coronary syndromes. The lauroyl cilostazol has the remarkable long-acting characteristic.

The invention belongs to the technical field of artificial intelligence, and discloses a diabetic complication risk deduction system based on a graph neural network and a knowledge graph, and the system comprises a physiological feature sensing module which collects physiological sensing data of a diabetic patient, carries out the time synchronization and normalization processing of the physiological sensing data, and carries out the prediction of the diabetic complication risk. Separating a stability characteristic component and a disturbance characteristic component; the pathological potential mapping module is used for mapping the stable characteristic component into a basic physiological node and mapping the disturbance characteristic component into a potential pathological activation node on the basis of a semantic structure of a knowledge graph, introducing a pathological potential function and establishing a pathological potential mapping network; the pathology activation recognition module calculates potential pathology energy of each potential pathology activation node in the pathology potential mapping network through a graph neural network, and when the potential pathology energy is greater than a preset potential pathology energy threshold, the potential pathology activation node is marked as a pathology activation source node; and early warning of diabetic complications is realized.

The present application relates to heterobicyclic compounds having glucagon-like peptide receptor (GLP-1R) agonist activity, processes for their preparation, pharmaceutical compositions comprising them and their use as GLP-1R agonists or for the treatment or prophylaxis of GLP-1R associated diseases or disorders. In particular, the compounds of the present application are useful for body weight management, for lowering blood sugar and / or for the treatment or prevention of diabetes, diabetic complications, obesity, overweight, dyslipidemia, fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)), metabolic diseases, cardiovascular diseases, nervous system disorders, mental disorders, kidney diseases, etc. , gastrointestinal diseases, autoimmune diseases, inflammatory diseases, lung diseases, hypothalamic-pituitary-gonad axis related diseases or disorders, cancers and the like.

The invention discloses a diabetic complication risk assessment method based on unequal-length CGM data, belongs to the field of assessment methods, and aims to solve the problem of how to extract complication related features from unequal-length CGM sequences of diabetic patients and realize efficient risk assessment on the premise of not losing dynamic information as far as possible. The method comprises the following steps: step 1, acquiring a multi-day CGM data sequence of a diabetic patient; 2, performing feature extraction based on the multi-day CGM data sequence to obtain a multi-day CGM sequence feature C; and step 3, inputting the multi-day CGM sequence feature C into the FCNN to obtain the probability that the diabetic suffers from complications.

The invention discloses a traditional Chinese medicine composition for treating type 2 diabetes and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from, by weight, 11-15 parts of radix acanthopanacis semticosi, 5-15 parts of male silkworm moth, 7-17 parts of white ginseng, 5-11 parts of rhizoma polygoni cuspidati, 15-25 parts of rhizoma coptidis, 1-5 parts of cortex cinnamomi, 11-15 parts of fructus ligustri lucidi, 11-15 parts of common fenugreek seed, 7-17 parts of lithocarpus litseifolius, 3-7 parts of raw radix astragali and 1-3 parts of wild lucid ganoderma. , 3-9 parts of tribulus terrestris and 11-17 parts of nigella nigra seeds. The traditional Chinese medicine composition has the effect of balancing and stabilizing blood sugar, is short in treatment course, quick in effect and free of toxic and side effects, and has an excellent curative effect on treating diabetic complications.

The invention discloses a feature selection method for multi-label prediction of diabetic complications, and relates to the technical field of machine learning and medical data processing. The method comprises the following steps: carrying out label layered independent weight calculation on original characteristics of diabetic complications and complication label data to obtain a label weight matrix of a plurality of complications; performing graph regularization optimization based on layered independent weights on the label weight matrix of the multiple complications, training a multi-label classification model, reducing irrelevant and redundant features in the multi-label classification model, and obtaining feature subsets with importance perception, high discrimination and robustness; and screening the original data of the diabetic complications by using the optimized multi-label classification model, calculating a feature contribution matrix, and for positive prediction labels, outputting the first three features of contribution values for constructing the features of diabetic complication prediction. According to the method, key features can be screened out, and the accuracy of model prediction is improved.

The application provides a traditional Chinese medicine compound medicine composed of Coptis chinensis, Astragalus membranaceus, Panax notoginseng and Rehmannia glutinosa and application thereof in preventing and treating diabetes and diabetes complications, and experimental results show that the compound medicine has good prevention and treatment effects on diabetes and various diabetes complications such as diabetic heart disease, diabetic kidney disease and diabetic retinopathy.

The present invention relates to the use of ligustrazine nitrone derivatives and pharmaceutical composition thereof for the treatment and prevention of diseases of diabetic complications, which include renal anemia. The ligustrazine nitrone derivatives have the structure of the general formula (I).Experimental results indicated that the ligustrazine nitrone derivatives can significantly increase the levels of serum iron and erythropoietin in STZ induced SD rats and spontaneously hypertensive rats, and can be used for treating and preventing renal anemia caused by decrease in renal EPO production and / or concomitant iron deficiency. Therefore, the ligustrazine nitrone derivatives can be made into various dosage forms with a drug carrier. The derivatives can be prepared into various dose forms together with drug carriers.

The application discloses a diabetes complication risk assessment method based on unequal length CGM data and belongs to the field of assessment methods. The application aims to solve the problem of how to extract the complication-related features from the unequal length CGM sequence of a diabetes patient and realize efficient risk assessment without losing dynamic information as much as possible. The application comprises the following steps: step 1, acquiring a multi-day CGM data sequence of a diabetes patient; step 2, performing feature extraction based on the multi-day CGM data sequence to obtain multi-day CGM sequence features; and step 3, inputting the multi-day CGM sequence features into an FCNN to obtain the probability of the diabetes patient suffering from complications. C ; step 3, inputting the multi-day CGM sequence features C into an FCNN to obtain the probability of the diabetes patient suffering from complications.

The invention discloses thiazolidinedione or a derivative thereof as well as a preparation method and application thereof, the structural formula of the thiazolidinedione or the derivative thereof is non-substituted or randomly substituted by at least one R, and R is halogen or hydroxyl. An activity detection experiment and a compound dissociation constant test experiment on the inhibition activity of aldose reductase and alpha-glucosidase on the compound prove that the compound disclosed by the invention is an efficient AKR1B1 / alpha-GC double-target inhibitor with excellent membrane permeability, and is capable of relieving hyperglycemia while preventing abnormal metabolism of polyhydric alcohols; by utilizing a double-target collaborative intervention strategy, the application prospect in preparation of related medicines for preventing and / or treating diabetic complications is good.

The present invention relates to novel compounds and pharmaceutical compositions thereof, and to methods for promoting healthy skin aging, treating skin disorders, treating cardiovascular disorders, treating renal disorders, treating angiogenesis disorders, such as cancer, treating tissue damage, such as non-cardiac tissue damage, treating progressive myocardial infarction, and treating various other disorders, such as complications resulting from diabetes with the compounds and compositions of the invention. Other disorders may include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, skin infections, peripheral vascular disease, stroke, and the like.

The invention belongs to the technical field of hippophae rhamnoides fruit residue utilization, and particularly relates to application of hippophae rhamnoides fruit residue extract in preparation of a medicine for treating diabetic complications. Experiments find that the sea buckthorn pomace extract has a high inhibition rate on cholesterol esterase and alpha-amylase, and the sea buckthorn pomace extract mainly contains malvacic acid, aspartic acid, luteolin and vernonic acid, and key targets mainly include IL6, AKT1, TNF and PPARG, and the sea buckthorn pomace extract has a high inhibition rate on cholesterol esterase and alpha-amylase. The fructus hippophae pomace extract plays a role in regulating blood fat regulation, atherosclerosis, HIF-1 signal transduction, AGE-RAGE signal transduction and other pathways in diabetic complications.

The present invention provides the use of pyruvate in the treatment of lipodystrophy syndrome, belonging to the technical field of endocrine and metabolic disease treatment. This invention proposes for the first time the use of pyruvate, such as sodium pyruvate and potassium pyruvate, in the treatment of lipodystrophy syndrome. It has been found that pyruvate can restore atrophic adipose tissue and improve the progression of diabetic complications and acute pancreatitis associated with hypertriglyceridemia, thereby increasing patient survival and improving overall prognosis.

The present invention provides a compound having a PDHK inhibitory activity and useful for the treatment or prophylaxis of diabetes (type 1 diabetes, type 2 diabetes etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract etc.), cardiac failure (acute cardiac failure, chronic cardiac failure), cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary disease, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension or Alzheimer disease. The present invention relates to a compound of the formula [I-a] or the formula [II], or a pharmaceutically acceptable salt thereof:wherein each symbol means the same as that described in the specification.

The invention belongs to the technical field of medicines, and particularly relates to preparation of CD317 + MSC cells and application of the CD317 + MSC cells to treatment of type 2 diabetes mellitus. The invention researches the characteristics of CD317 + cells in a heterogeneous UC-MSC population, and finds that the FACS is more beneficial to screening of CD317 + MSCs, and the number of the CD317 + MSCs is gradually increased in in-vitro culture. The expression quantity of stem cell characteristic-related genes in the CD317 + MSC subgroup is obviously increased, which indicates that the stem cell is possibly in an undifferentiated state or affects the differentiation potential, but the effect is transiently and gradually weakened along with culture, which explains that the pluripotent differentiation potential and the like are not obviously changed and are not associated with other potential stem cell surface antigens. The research also finds that the cell is a more favorable subgroup, has unique pluripotency and repair / substitution characteristics, can realize stem cell rejuvenation phenotype, can improve pancreas beta cell functions, reduces diabetic complications, enables partial patients to be independent of insulin, and improves the treatment effect on type 2 diabetes mellitus.

This invention belongs to the field of artificial intelligence technology. It discloses a risk prediction system for diabetic complications based on graph neural networks and knowledge graphs. The system includes a physiological feature perception module, which collects physiological perception data from diabetic patients, performs time synchronization and normalization on the data, and separates stable and perturbation feature components; a pathological potential mapping module, which, based on the semantic structure of the knowledge graph, maps stable feature components to basic physiological nodes and perturbation feature components to potential pathological activation nodes, introduces a pathological potential function, and establishes a pathological potential mapping network; and a pathological activation identification module, which calculates the potential pathological energy of each potential pathological activation node in the pathological potential mapping network using a graph neural network. When the potential pathological energy exceeds a preset potential pathological energy threshold, it is marked as a pathological activation source node; thus achieving early warning of diabetic complications.

The invention relates to the technical field of diabetic complication prediction, and discloses a modeling method of a diabetic complication prediction model. The method comprises the following steps: collecting clinical index data of a patient, including blood glucose level, blood pressure value, blood fat content and renal function parameters, and performing standardization processing to generate a standard data set; time sequence features in the data set are extracted, the short-term fluctuation trend and the long-term change rule of each index are calculated through a sliding window algorithm, and a time sequence feature vector is generated; and inputting the vector into a deep feature extraction network formed by multilayer convolution and long and short term memory units, and extracting high-dimensional time sequence feature representation. Based on the representation, a hierarchical clustering algorithm is used for grouping patient groups, and personalized complication risk prediction sub-models are constructed for different groups. And integrating the outputs of all the personalized sub-models, and generating a final diabetic complication prediction result through a weighted voting mechanism.

This invention discloses an optimization method and system for a predictive model of diabetic complications. It involves collecting routine laboratory test data from diabetic patients, performing preprocessing such as missing value removal, label merging, and SMOTE resampling to construct a balanced dataset. The average importance of indicators is evaluated using multiple machine learning models to select a subset of key features. Random forest, XGBoost, support vector machine, and multilayer perceptron are selected as base classifiers, and after hyperparameter optimization, a stacked ensemble learning model is constructed to further improve predictive performance. Finally, the model is packaged as an API service and embedded into a hospital information system to achieve high-precision, low-cost, and real-time risk prediction of diabetic complications. Experimental results show that this invention achieves an accuracy of 98.5% and an AUC of 99.76% in predicting diabetic nephropathy complications, outperforming single models.

The present application relates to the preparation of new physiological and pharmaceutically active molecules, and belongs to the field of pharmaceutical synthesis chemistry, and relates to the design and preparation of a class of molecules capable of inhibiting the activity of human kallikrein. Firstly, fluoroacrylic acid and alcohol compounds are used as raw materials to obtain a class of fluoroallyl alcohol compounds; then the fluoroallyl alcohol is condensed with carboxylic acid compounds to obtain fluoroallyl carboxylic acid ester compounds with general formula (I) capable of inhibiting the activity of human kallikrein. The compounds are considered to be useful for treating diabetic complications, eye diseases and edema-related diseases. In addition, they have potential applications in the diagnosis and treatment of some cancers.

The invention provides a pharmaceutical active ingredient composition and application thereof in treating diabetes or preventing and treating diabetic complications. The pharmaceutical active ingredient composition provided by the invention comprises a first active ingredient and a second active ingredient, the first active component is at least one of the following components: a DPP-4 inhibitor, pharmaceutically acceptable salts, esters, prodrugs and metabolites thereof, and an SGLT-2 inhibitor, pharmaceutically acceptable salts, esters, prodrugs and metabolites thereof; the second active ingredient is at least one of the following components: coenzyme Q10, pharmaceutically acceptable ester of the coenzyme Q10, R-alpha-lipoic acid, pharmaceutically acceptable salt and ester of the R-alpha-lipoic acid, glutathione, pharmaceutically acceptable salt of the glutathione, resveratrol and pharmaceutically acceptable ester of the resveratrol. The pharmaceutical active ingredient composition provided by the invention has a good hypoglycemic effect, and has remarkable advantages in the aspects of relieving oxidative stress and preventing and treating diabetic complications.

The invention discloses onium salt derivatives containing tetrahydropyran side chains as well as a preparation method and application of the onium salt derivatives. The structure of the compound also comprises isomers, solvates and pharmaceutically acceptable salts thereof, and the compound has good inhibitory activity on alpha-glucosidase, and can improve glycolipid metabolism disorder of diabetic nephropathy model mice and protect renal functions. The compound enriches the structure type of the existing alpha-glucosidase inhibitor, and has the potential of preventing or treating hyperglycemia, diabetic complications, obesity, abnormal lipid metabolism or hypertension.

The application discloses a feature selection method for multi-label prediction of diabetic complications, and relates to the technical fields of machine learning and medical data processing. The method comprises the following steps: performing label stratified independent weight calculation on original features and complication label data of the diabetic complications to obtain a plurality of label weight matrices of the complications; performing graph regularization optimization based on the stratified independent weight on the label weight matrices of the complications, training a multi-label classification model, reducing irrelevant and redundant features in the multi-label classification model, and obtaining an important feature subset which is important, has high discriminability and is robust; filtering original data of the diabetic complications by using the optimized multi-label classification model, calculating a feature contribution matrix, and outputting features with top three contribution values for positive prediction labels to construct features for prediction of the diabetic complications. The method can screen out key features and improve the prediction accuracy of the model.

We provide safe mitochondrial uncoupling agents. [Solution] The present invention provides 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole, a novel phenyl derivative, or a pharmaceutically acceptable salt thereof. This compound is useful for regulating mitochondrial activity, reducing obesity, and treating diseases including diabetes and diabetic complications.

The invention discloses a targeting stem cell exosome composition and application thereof in treating diabetic foot ulcer. According to the composition, a mesenchymal stem cell exosome is modified through genetic engineering, specific targeting fusion polypeptide is expressed on the surface of the mesenchymal stem cell exosome, anti-inflammatory miR-146a and a pro-angiogenic factor VEGF are loaded, and then the mesenchymal stem cell exosome is compounded with temperature-sensitive hyaluronic acid hydrogel to form a sustained release system. The sequence of the fusion polypeptide is as shown in SEQ ID NO: 1, and the targeting of exosomes to diabetic inflammation parts is remarkably improved; the stability of miR-146a is enhanced through chemical modification, and the miR-146a cooperates with VEGF to inhibit inflammation and promote revascularization. In-vitro experiments show that the composition reduces the levels of TNF-alpha and IL-6 by 85% and 88% respectively, and the cell migration rate reaches 99.3%; in-vivo experiments show that the wound healing rate of diabetic rats reaches 99.6% on the 14th day, and the collagen deposition area proportion is increased to 77.5%. The invention has targeting property, function synergy and slow release performance, and provides an efficient treatment strategy for diabetic foot ulcer.

The invention belongs to the field of biological pharmacy, and relates to a dipeptidyl peptidase IV inhibitory oligopeptide and application thereof. Specifically, the DPP-IV inhibitory peptide is designed by computer-aided design. The polypeptide with DPP-IV inhibitory activity is screened out through virtual amino acid mutation, online database prediction, molecular docking and other methods. The invention proves that the LAFPGSW polypeptide can obviously improve the physiological indexes of diabetic mice, has no toxic or side effect, and can relieve the change of mouse liver weight and mouse body weight caused by diabetes, so that the mouse liver weight and the mouse body weight are recovered to a normal level; according to the present invention, the compound can significantly reduce the levels of AST, ALT, TC and TG in serum, and relieve LDL-C and HDL-C abnormality, such that the compound has effects of blood sugar lowering, lipid lowering, insulin secretion promoting, insulin resistance improving and the like, and can be used for prevention and treatment of diabetes and diabetic complications.

The invention belongs to the technical field of disease treatment, and particularly relates to a composition for regulating blood sugar and microvascular homeostasis and a preparation method thereof. The composition for regulating the blood sugar and the microvascular homeostasis is prepared from the following components in parts by mass: 380 to 520 parts of peony seed oil, 260 to 440 parts of dihydromyricetin and 0.025 to 0.062 part of chromium picolinate. The composition for regulating blood sugar and microvascular homeostasis can be used for protecting microvessels, regulating blood sugar, improving microcirculation of the whole body and preventing diabetic complications, and is suitable for preventing and treating diseases such as hyperglycemia, hyperlipidemia and glycolipid metabolism syndrome. Experiments on vascular endothelial dysfunction of obese rats show that the composition disclosed by the invention can be used for remarkably improving microvascular endothelial functions of the obese rats and effectively delaying rise of arterial blood pressure. Experiments on mouse diabetic cardiomyopathy find that the composition has a definite myocardial protection effect on DCM mice.

A pharmaceutical composition comprising a GLP-1 and GIP dual-receptor agonist and use thereof. Specifically, the pharmaceutical composition comprises the GLP-1 and GIP dual-receptor agonist, a stabilizer, a buffer salt, and a bacteriostatic agent. In the provided pharmaceutical composition, auxiliary materials such as the stabilizer, the buffer salt, and the bacteriostatic agent are selected and added, such that the polypeptide GLP-1 and GIP dual-receptor agonist serving as a pharmaceutical active ingredient has good solubility in a liquid formulation. Meanwhile, the problems of drug failure and the like caused by the polymerization of the agonist are avoided, and the pharmaceutical composition has good stability and antibacterial efficacy and meets the requirements of a multi-dose injection. The pharmaceutical composition exhibits an important application prospect in the prevention and treatment of metabolic disorder-related diseases such as diabetes or diabetic complications and obesity or obesity complications.

The invention provides a pharmaceutical composition for treating diabetic complications and application thereof. Research finds that after effective parts such as coptis chinensis and radix puerariae are combined, the composition has obvious influence on diabetic complications and has a certain treatment effect. Specifically, the invention provides application of a coptis chinensis and kudzu vine root composition in preparation of a medicine for treating diabetic skin ulcer. The rhizoma coptidis and radix puerariae composition is prepared from the following raw materials in parts by weight: 1 to 10 parts of rhizoma coptidis alkaloid and 1 to 10 parts of rhizoma coptidis polysaccharide; the kudzuvine root extract is prepared from 1-10 parts by weight of kudzuvine root flavone, 1-10 parts by weight of kudzuvine root polysaccharide and 1-10 parts by weight of kudzuvine root saponin.

The invention belongs to the technical field of medicine, and provides a traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preventing and treating diabetes mellitus, the traditional Chinese medicine composition comprises concha arcae, radix scrophulariae, rhizoma anemarrhenae, ginseng, radix astragali, prepared rehmannia root, dogwood, Chinese yam, moutan bark, poria cocos, radix puerariae, rhizoma atractylodis, radix salviae miltiorrhizae, earthworm, stiff silkworm and rhizoma alismatis. The invention provides a novel pharmaceutical composition for preventing and treating diabetes, which is reasonable in formula and exact in curative effect. The traditional Chinese medicine composition not only can effectively reduce blood sugar and improve core symptoms of diabetes mellitus, but also can treat diabetic complications in a targeted manner, especially can achieve synergistic prevention and treatment of diabetic feet, and solves the limitation that most of existing medicines only aim at a single symptom.